title: Resistin is an indicator of the metabolic syndrome according to five different definitions in the Finnish Health 2000 survey.
abstract: BACKGROUND
  Resistin is a peptide hormone secreted mainly from human monocytes and macrophages. It has an unclear association with the metabolic syndrome, which is a cluster of cardiovascular risk factors such as glucose intolerance, central obesity, insulin resistance, dyslipidemia, and hypertension. We examined the association of resistin with metabolic syndrome and its components in a population-based cohort.
  
  
  METHODS
  A subsample of a large Finnish cross-sectional health examination survey (the Health 2000 Survey) was studied. Resistin was measured using an in-house assay based on the DELFIA® technique in 1,508 Finnish men and women aged 45-74 years. Metabolic syndrome was defined according to five different definitions.
  
  
  RESULTS
  Resistin levels were higher in the subjects with metabolic syndrome when compared to the subjects without metabolic syndrome (P < 0.05 for every metabolic syndrome criterion). In logistic regression analysis, a high resistin level was an independent predictor of the prevalence of metabolic syndrome (P < 0.05 for every criterion). Resistin was positively associated with waist circumference, tumor necrosis factor-α, and insulin resistance assessed by the homeostasis model and inversely with total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol after adjusting for age, gender, and body mass index (P < 0.05 for all).
  
  
  CONCLUSIONS
  These results clarify the controversial association of resistin in obesity and metabolic syndrome, suggesting that a high resistin level is associated with clustering of metabolic disturbances.
authors.affiliation: Institute of Clinical Medicine, Department of Internal Medicine and Biocenter Oulu, University of Oulu, Oulu, Finland. elina.malo@oulu.fi
authors.forename: Elina
authors.initials: E
authors.lastname: Malo
authors.forename: Olavi
authors.initials: O
authors.lastname: Ukkola
authors.forename: Maarit
authors.initials: M
authors.lastname: Jokela
authors.forename: Leena
authors.initials: L
authors.lastname: Moilanen
authors.forename: Mika
authors.initials: M
authors.lastname: Kähönen
authors.forename: Markku S
authors.initials: MS
authors.lastname: Nieminen
authors.forename: Veikko
authors.initials: V
authors.lastname: Salomaa
authors.forename: Antti
authors.initials: A
authors.lastname: Jula
authors.forename: Y Antero
authors.initials: YA
authors.lastname: Kesäniemi
mesh_terms: D000368:Aged; D015331:Cohort Studies; D003430:Cross-Sectional Studies; D003940:Diagnostic Techniques, Endocrine; D005260:Female; D005387:Finland / Q000453:epidemiology; D006305:Health Status Indicators; D006306:Health Surveys; D006801:Humans; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000175:diagnosis* / Q000453:epidemiology / Q000209:etiology*; D008875:Middle Aged; D015995:Prevalence; D052243:Resistin / Q000097:blood / Q000502:physiology*; D012307:Risk Factors
chemical_list: C499624:RETN protein, human; D052243:Resistin